-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Medical Cube will officially release a new report "2021 Transaction Analysis of Chinese Biopharmaceutical Enterprises"
.
The report makes an in-depth analysis of the transaction projects and characteristics of domestic companies in recent years, and summarizes and looks forward to the overall trend of transaction projects last year
.
With the improvement of innovative drug policy environment and financing channels, domestic project transactions have gradually transitioned from the introduction of overseas projects in the early stage to the transformation of their own products that can go abroad and be authorized to overseas enterprises
.
Although the global project transactions in the past 2021 increased by only 7% compared with 2020, the overall popularity remains unabated.
The total disclosed transaction amount exceeds 170 billion US dollars, and the pharmaceutical transaction activity in China is second only to the United States, ranking first in the world.
Second in the world
.
This year's China biopharmaceutical enterprise transaction report reveals the following four trends: Interpretation of the report On March 24, 2022, Medicinal Cube will broadcast the detailed content of the report, and industry peers are welcome to participate in the discussion, sign up for the live broadcast and receive the "2021 Annual Report".
Please scan the QR code of the poster below
.
Data source The data source of "Transaction Analysis of Chinese Biopharmaceutical Enterprises in 2021" is based on the NextPharma global new drug database, and covers the information publicly disclosed by various new drug R&D companies
.
The NextPharma Global New Drug Database is an innovative data product launched by the Medical Cube.
It focuses on the global pharmaceutical industry, highly integrates and standardizes the patent information, registration application, academic literature, clinical information, news intelligence, market sales, and construction of global innovative drugs.
It has developed a unique disease atlas and target atlas, currently including more than 4,000 targets around the world, about 30,000 preclinical, clinical phase I-III and marketed drugs
.
In this report, the scope of data analyzed is mainly the transactions related to Chinese domestic enterprises in 2021 provided in the NextPharma transaction module of Pharma Cube ;The trend analysis is mainly based on project transactions, unless otherwise specified, does not include company mergers and acquisitions information
.
List of reports
.
The report makes an in-depth analysis of the transaction projects and characteristics of domestic companies in recent years, and summarizes and looks forward to the overall trend of transaction projects last year
.
With the improvement of innovative drug policy environment and financing channels, domestic project transactions have gradually transitioned from the introduction of overseas projects in the early stage to the transformation of their own products that can go abroad and be authorized to overseas enterprises
.
Although the global project transactions in the past 2021 increased by only 7% compared with 2020, the overall popularity remains unabated.
The total disclosed transaction amount exceeds 170 billion US dollars, and the pharmaceutical transaction activity in China is second only to the United States, ranking first in the world.
Second in the world
.
This year's China biopharmaceutical enterprise transaction report reveals the following four trends: Interpretation of the report On March 24, 2022, Medicinal Cube will broadcast the detailed content of the report, and industry peers are welcome to participate in the discussion, sign up for the live broadcast and receive the "2021 Annual Report".
Please scan the QR code of the poster below
.
Data source The data source of "Transaction Analysis of Chinese Biopharmaceutical Enterprises in 2021" is based on the NextPharma global new drug database, and covers the information publicly disclosed by various new drug R&D companies
.
The NextPharma Global New Drug Database is an innovative data product launched by the Medical Cube.
It focuses on the global pharmaceutical industry, highly integrates and standardizes the patent information, registration application, academic literature, clinical information, news intelligence, market sales, and construction of global innovative drugs.
It has developed a unique disease atlas and target atlas, currently including more than 4,000 targets around the world, about 30,000 preclinical, clinical phase I-III and marketed drugs
.
In this report, the scope of data analyzed is mainly the transactions related to Chinese domestic enterprises in 2021 provided in the NextPharma transaction module of Pharma Cube ;The trend analysis is mainly based on project transactions, unless otherwise specified, does not include company mergers and acquisitions information
.
List of reports
